Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Madrigal Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$321.10M. For fiscal 2025 it was -$298.59M. The highest annual figure on record is $81.77M in fiscal 2009.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$298.59M | – |
| FY2024 | Dec 31, 2024 | -$496.78M | – |
| FY2023 | Dec 31, 2023 | -$379.97M | – |
| FY2022 | Dec 31, 2022 | -$293.10M | – |
| FY2021 | Dec 31, 2021 | -$242.08M | – |
| FY2020 | Dec 31, 2020 | -$206.20M | – |
| FY2019 | Dec 31, 2019 | -$94.86M | – |
| FY2018 | Dec 31, 2018 | -$40.59M | – |
| FY2017 | Dec 31, 2017 | -$31.99M | – |
| FY2016 | Dec 31, 2016 | -$25.22M | – |
| FY2015 | Dec 31, 2015 | -$2.57M | – |
| FY2014 | Dec 31, 2014 | -$83.28M | – |
| FY2013 | Dec 31, 2013 | -$87.04M | – |
| FY2012 | Dec 31, 2012 | -$60.20M | – |
| FY2011 | Dec 31, 2011 | -$43.97M | – |
| FY2010 | Dec 31, 2010 | -$34.97M | -142.8% |
| FY2009 | Dec 31, 2009 | $81.77M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$55.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$92.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$59.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$113.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$46.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$78.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$66.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$116.01M | – |
| Q2 FY2024 | Jun 30, 2024 | -$162.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$151.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$117.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$98.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$86.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$78.21M | – |
| Q4 FY2022 | Dec 31, 2022 | -$85.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$80.29M | – |
| Q2 FY2022 | Jun 30, 2022 | -$70.16M | – |
| Q1 FY2022 | Mar 31, 2022 | -$57.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$64.50M | – |
| Q3 FY2021 | Sep 30, 2021 | -$63.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$61.65M | – |
| Q1 FY2021 | Mar 31, 2021 | -$52.87M | – |
| Q4 FY2020 | Dec 31, 2020 | -$59.44M | – |
| Q3 FY2020 | Sep 30, 2020 | -$58.67M | – |
| Q2 FY2020 | Jun 30, 2020 | -$50.21M | – |
| Q1 FY2020 | Mar 31, 2020 | -$37.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$29.93M | – |
| Q3 FY2019 | Sep 30, 2019 | -$24.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -$22.68M | – |
| Q1 FY2019 | Mar 31, 2019 | -$18.09M | – |
| Q4 FY2018 | Dec 31, 2018 | -$14.43M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.31M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.80M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.05M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.85M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.63M | – |
See a number that looks wrong?